The battery-free percutaneous sacral neuromodulation system has comparable efficacy to published rates for traditional sacral neuromodulation devices. The US Food and Drug Administration (FDA) has ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal ...
Fewer punctures and shorter surgical time reported for sacral neuromodulation with 3D printing and ultrasound localization. (HealthDay News) — For patients with neurogenic bladder and pelvic ...
SAN JOSE, Calif., June 18, 2025 /PRNewswire/ -- Neuspera ® Medical, Inc., the leading developer of integrated technologies powering the future of neuromodulation, today announced that the U.S. Food ...
Axonics Inc. received FDA approval for its recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS) for bladder and bowel dysfunction. The F15’s primary cell requires no recharging ...
Axonics (NASDAQ:AXNX) said it acquired a lead placement solution from Radian which complements the company's existing sacral neuromodulation (SNM) offering. The company acquired the assets of Radian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback